Angiogenesis and inflammation are crucial processes through which the tumor microenvironment (TME) influences tumor progression. In this study, we showed that peroxisome proliferator-activated receptor c (PPARc) is not only expressed in CT26 and 4T1 tumor cell lines but also in cells of TME, including endothelial cells and tumor-associated macrophages (TAM). In addition, we showed that rosiglitazone may induce tumor vessel normalization and reduce TAM infiltration. Additionally, 4T1 and CT26 tumor-bearing mice treated with rosiglitazone in combination with radiotherapy showed a significant reduction in lesion size and lung metastasis. We reported that a single dose of 12 Gy irradiation strongly inhibits local tumor angiogenesis. Secretion of C-C motif chemokine ligand 2 (CCL2) in response to local irradiation facilitates the recruitment of migrating CD11b + myeloid monocytes and TAM to irradiated sites that initiate vasculogenesis and enable tumor recurrence after radiotherapy. We found that rosiglitazone partially decreases CCL2 secretion by tumor cells and reduces the infiltration of CD11b + myeloid monocytes and TAM to irradiated tumors, thereby delaying tumor regrowth after radiotherapy. Therefore, combination of the PPARc agonist rosiglitazone with radiotherapy enhances the effectiveness of radiotherapy to improve local tumor control, decrease distant metastasis risks and delay tumor recurrence.
been shown to play a pivotal part, both structurally and functionally, in tumor angiogenesis, progression and response to treatment. 8, 9 Based on preclinical and clinical studies, stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) has better antitumor efficacy than conventional fractionated radiation therapy. High single fraction doses (8) (9) (10) (11) (12) (13) (14) (15) (16) Gy) induce endothelial cell dysfunction and apoptosis and cause serious damage to the tumor vasculature accompanied by indirect tumor cell death. [10] [11] [12] Irradiation blocks local tumor angiogenesis, whereas vasculogenesis, as a backup pathway, recovers tumor blood supply to enable tumor regrowth or recurrence after RT. Proangiogenic myeloid-derived cells such as tumor-associated macrophage (TAM), 13 Tie-2-expressing monocytes (TEM), 14 CD11b + myeloid cells 15 and myeloid-derived suppressor cell (MDSC) 16 participate in vasculogenesis.
In general, peroxisome proliferator-activated receptor c (PPARc)
is a ligand-activated transcription factor that has anti-inflammatory, antiangiogenic and antineoplastic activities based on preclinical data. 17, 18 PPARc deletion in mouse macrophages not only facilitates mammary tumor progression but also weakens the anti-tumor effects of the PPARc agonist rosiglitazone accompanied by increased infiltration of CD11b + myeloid cells and TAM of proinflammatory and proangiogenic phenotypes. 19 With the increasing knowledge of tumor angiogenesis and inflammation, antiangiogenic or anti-inflammatory treatment modalities have emerged as novel research topics.
PPARc agonists have been intensively evaluated as a promising new
therapeutic strategy in the treatment of cancer. However, their effect on the tumor vasculature and cancer-related inflammation remains poorly explored. Angiogenesis and inflammation are crucial processes, through which the TME influences tumor radioresponse.
The aim of the present study is to evaluate the synergistic effect of the PPARc agonist rosiglitazone and RT.
| MATERIALS AND METHODS

| Cell culture and in vitro irradiation
The murine colon carcinoma cell line CT26, breast cancer cell line 4T1, RAW264.7 macrophages, HUVEC and THP-1 cells were gifted from the State Key Laboratory of Biotherapy of West China Hospital. Cells were cultured in DMEM or RPMI 1640 (HyClone, Logan, UT, USA) containing 10% FBS (Roche, Basel, Switzerland) and 1%
penicillin/streptomycin (HyClone) and incubated at 37°C in 5% CO 2 .
Cells were irradiated (distance from X-ray source to the target was 30 cm) at a dose rate of 4 Gy/min using an X ray-generator (XRAD320; Precision X-ray Inc., North Branford, CT, USA). Sham irradiation involved placing cell culture plates at a similar temperature for the length of irradiation.
| Animals
Female BALB/c mice 6-8 weeks of age were purchased from the Chinese Academy of Medical Science. The animals were maintained under specific pathogen-free conditions and used according to Institutional Animal Care and Use Guidelines (no. SYXK2007-008 , the mice were randomly divided into 4-6 groups for CT26 (n = 6 for each group) and 4T1 models (n = 6
for each group). To investigate the therapeutic effect of rosiglitazone combined with RT, the mice were given 100 mg/kg rosiglitazone (Selleck Chemicals, Houston, TX, USA) or vehicle (DMSO:PEG300:
Tween80:ddH 2 O = 4:30:5:100) by oral gavage per day for 2 weeks.
Before 6 or 12 Gy irradiation, each mouse was anesthetized and shielded by a lead box with only the tumor exposed. Tumor diameters were measured every 2 or 3 days using digital calipers, and the tumor volume was calculated by the formula: volume = length 9 width 9 width 9 0.5.
| Clonogenic survival assays
CT26 or 4T1 cells were plated in 6-well plates at various densities and treated with 40 lmol/L rosiglitazone or vehicle 1 hour prior to irradiation at various doses. 20 After 2 weeks of incubation, surviving colonies containing at least 50 cells were counted. Survival fraction was calculated, and then radiation dose-survival curves, radiobiological parameters and sensitizing enhancement ratio were determined using 
| Cell chemotaxis assays
Cell chemotaxis assays were carried out using 8.0 lm pore size transwells (Corning, Corning, NY, USA). CT26 cells were exposed to Figure S1 . The data were analyzed using FlowJo v10.0 software (Treestar Inc., Ashland, OR, USA).
| Lung metastasis quantification
Lungs from 4T1 tumor-bearing mice were obtained 32 days after s.c.
inoculation. H&E staining was used to quantify lung metastasis.
| In vivo lung imaging
4T1 tumor-bearing mice were anesthetized with isoflurane gas inhalation. Lung microcomputed tomography (CT) was done on a Quantum GX microCT Imaging System (standard 4 minutes, field of view = 36 mm), and used for 3-D reconstruction with a volume-rendering technique. Then, gross tumor volumes, lungs and bones were delineated on every section of the CT scans by the software Caliper Analyze.
| Statistical analysis
Results are expressed as means AE SEM. Statistical tests were carried out using ANOVA and unpaired Student's t tests as required. Differences were considered statistically significant for P-values <.05. All data were analyzed using SPSS v22.0 (IBM, Armonk, NY, USA). 
| Rosiglitazone remodels the tumor vasculature, decreases intratumoral hypoxia and TAM infiltration and improves vessel perfusion
Abnormal tumor vasculatures lead to a hypoxic and immunosuppressive TME that facilitates tumor progression, invasion and radioresistance. 6 Before treatment, we collected some tumor samples as 
| Rosiglitazone reduces tumor-derived CCL2 levels and restricts recruitment of myeloid cells or TAM to irradiated tumors, which delays tumor regrowth by disrupting vasculogenesis after HFRT
Hypofractionated irradiation therapy significantly delayed tumor progression. However, 2 weeks after HFRT, tumors in the HFRT group started to regrow. HFRT plus rosiglitazone was more effective in controlling tumor regrowth than was HFRT alone ( Figure 6A ). Next, we investigated the effect of HFRT on local angiogenesis. Two weeks after HFRT, the irradiated tumors had fewer endothelial cells and pericytes than the vehicle-treated unirradiated tumors (Figure 6B) . Thereby, 12 Gy HFRT significantly abrogated local angiogenesis, which contributes to tumor regression. However, when the tumors had completely relapsed 4 weeks after HFRT, endothelial cell Figure 6C,D) . In addition, using flow cytometry, we observed an increasing infiltration of leukocyte subsets within CT26 tumors after HFRT ( Figure S1 ). Specifically, we found an increase in CD11b + myeloid monocytes ( Figure 6E ) and TAM ( Figure 6F ), which can be inhibited by rosiglitazone. In contrast,
we detected no change in TAN recruitment ( Figure 6G ).
CCL2 is an important chemoattractant involved in the recruitment of monocytes or TAM. 21 We used ELISA to assess the potentiality of CT26 and 4T1 cells to produce CCL2 in response to irradiation. As expected, irradiation promoted CT26 and 4T1 cells to secrete CCL2 in a dose-dependent method. However, compared with irradiation alone, irradiation combined with rosiglitazone treatment significantly reduced the level of CCL2 in both cell supernatant and serum ( Figure 7A,B) . Similarly, immunofluorescence staining for CCL2 showed that HFRT evidently upregulated CCL2 production, whereas rosiglitazone inhibited the expression of CCL2 in CT26 tumors after HFRT ( Figure 7C ). Next, Transwell chemotaxis assays were carried out to determine the importance of tumor-derived CCL2 in recruiting TAM to the TME. Rosiglitazone inhibited the chemotactic migration of RAW264.7 macrophages ( Figure 7D ). Thus, rosiglitazone may reduce CCL2 secretion from tumors and reduces TAM infiltration to irradiated tumors.
| DISCUSSION
In the present study, we showed that the PPARc agonist rosiglitazone exerts antiangiogenic and antineoplastic effects that inhibit the proliferative, invasive and metastatic potential of tumor cells ( Figure 8A ). RT displays prominent synergy with rosiglitazone that delays tumor recurrence by reducing the recruitment of myeloid F I G U R E 4 Rosiglitazone and radiotherapy exert a synergistic antitumor effect. A-E, CT26 and 4T1 tumor growth curves. Data are presented mean AE SEM (n = 6 mice/group). Rosig, rosiglitazone. *P < .05, **P < .01, ***P < .001; ns, non-significant. Radiation dose-survival curves of ( D) were captured within randomly selected fields (4-6 fields per tumor, n = 6 mice). E-G, Flow cytometry analysis shows the effect of rosiglitazone on the infiltration of leukocyte subsets within CT26 tumors. Quantification of (E) myeloid monocytes, (F) TAM and (G) tumorassociated neutrophils (TAN). Data are presented as mean AE SEM (n = 6). *P < .05, **P < .01, ***P < .001; ns, non-significant monocytes and TAM to irradiated tumors and by disrupting vasculogenesis after RT ( Figure 8B ). Moreover, giving rosiglitazone does not affect the weight of CT26-or 4T1-tumor bearing mice ( Figure S2 ).
Radioresponse is closely related to the TME. Recently, angiogenesis inhibitors, especially those targeting the VEGF signaling pathway, have made significant breakthroughs in cancer treatment from both clinical and preclinical perspectives. 22 Consequently, angiogenesis inhibitors have been shown to improve the efficacy of RT, 23, 24 thereby emerging as a novel therapeutic strategy. However, intrinsic or evasive resistance against antiangiogenic therapies is an intractable problem. 25 Accordingly, the exploration of a novel antiangiogenic and therapeutic target is necessary and important.
More than 20 years have passed since the PPAR subgroups were first discovered. 26 Rosiglitazone, one of the synthetic ligands of PPARc with highly pharmacological specificity, selectivity and affinity, shows potentially antitumor and antiangiogenic effects. 17 However, there are only a handful of studies investigating whether the antitumor effect of rosiglitazone is mediated only by its inhibitory effect on the tumor vasculature. Normalization of the tumor vasculature (an emerging concept in antiangiogenic therapy) leads to a more efficient delivery of blood and oxygen to cancer cells that can improve the antineoplastic efficacy of chemotherapy or RT. 27 We discovered that rosiglitazone promotes vascular normalization, and these results may provide a fresh insight into the effect of rosiglitazone on improving radioresponse. We showed that rosiglitazone exerts these antiangiogenic effects by inhibiting the proangiogenic VEGF/VEGFR2 signaling pathway in vitro. VEGFA is the master regulator of angiogenesis, binding to VEGFR2 to stimulate the proliferation of endothelial cells through the RAS-RAF-MAPK-ERK signaling pathway. VEGFA triggers endothelial F I G U R E 7 Rosiglitazone decreases the ability of CT26 and 4T1 cells to produce C-C motif chemokine ligand 2 (CCL2) in response to radiotherapy and inhibits the chemotactic migration of RAW264.7 macrophages. CCL2 levels in culture (A) supernatant (n = 4) or (B) blood serum (n = 6) were determined by ELISA. C, Immunofluorescence staining for CCL2 from CT26 tumors. Scale bar, 50 lm. Immunofluorescence images were captured within randomly selected fields (4-6 fields per tumor, n = 6 mice). D, Representative images and quantification of chemotactic migration of RAW264.7 macrophages (n = 3). Scale bar, 100 lm. Data are presented mean AE SEM. *P < .05, **P < .01, ***P < .001; ns, non-significant Rosiglitazone also decreased the expression levels of VEGF in human glioblastoma cells and murine Lewis lung carcinoma. 29 The hypoxic TME elicits neovascularization in a HIF-dependent method by mediating the recruitment of bone marrow-derived cells to orthotopic glioblastomas. 30 Further evidence indicates that MMP9-expressing bone marrow-derived myelomonocytes are sufficient to activate the angiogenic switch and are essential for the process of vasculogenesis;
thus, these cells might become a novel therapeutic target for adjuvant therapy after HFRT. 31 Therefore, it is reasonable to speculate that rosiglitazone delays vasculogenesis by reducing the production of these proangiogenic factors.
The synergistic interaction between rosiglitazone and RT is evi- Tumor-derived CCL2 is reported to be crucial for the recruitment of inflammatory monocytes and TAM to the TME. 7 High numbers of TAM and inflammatory monocytes and high levels of CCL2 have been shown to be correlated with poor prognosis in some carcinomas, such as breast cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma. [34] [35] [36] Tumor-derived CCL2 preferentially recruits inflammatory monocytes to promote lung metastases.
37
CCL2 also stimulates the recruitment of metastasis-associated macrophages (MAM) which is essential for extravasation and persistent growth of breast cancer cells. 38, 39 Here, we showed that rosigli- Therefore, the CCL2-mediated inflammatory response can be considered a novel therapeutic target for improving the efficacy of RT.
In conclusion, we provide evidence that the PPARc agonist 
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